688687 Beijing Kawin Technology Share-Holding
- 27.90
- +0.32+1.16%
Beijing Kawin Technology Share-Holding News
Kain Technology (688687) In-depth Report: Kailiwei, a new hepatitis C drug, is expected to create a second growth curve by selling probiotics derived from the new hepatitis B drug currently being developed by China and China
Kellyne Technology (688687): Kailliwei's sales revenue increased by more than 200% year-on-year, and probiotic hepatitis B indications are progressing in an orderly manner
Capital Securities released a research report on April 14 stating that it maintains Kain Technology (688687.SH) purchase rating. The main reasons for the rating include: 1) Kailiwei's revenue and profitability continue to increase, and Kim Shu-hee still h
Kellyne Technology (688687): Kailiwei's rapid release drives rapid performance growth, long-acting interferon-derived probiotics completed phase III clinical trials
Kain Technology (688687): Contrary growth shows resilience and is optimistic that subsequent risks will be cleared
Kellyne Technology (688687): Kailiwei achieved strong growth and production of long-acting interferon is about to be reported
Kane Technology (688687) 2023 Annual Report 2024 Quarterly Report Comment: Kailiwei's sales have increased dramatically, and the subsequent product pipeline is sufficient
Minsheng Securities released a research report on April 10 stating that it gave Kain Technology (688687.SH) a recommended rating. The main reasons for the rating include: 1) focusing on the anti-virus field, with a steady main business; 2) deepening marke
Kane Technology (688687) Annual Report Review Report: Kailiwei achieved ultra-rapid growth in 2023 and subsequent volume is expected to accelerate
Kain Technology (688687): Shuxi Gathered and Launched Long-lasting Interferon in 23 years, production is imminent
Kain Technology (688687): Innovative hepatitis C products can be expected to be released, clinical cure for hepatitis B is about to be realized
Kane Technology (688687): The Nuggets Hepatitis Market is building a moat with many varieties
Kailiwei Technology (688687): Kailiwei's rapid release hepatitis B R&D pipeline is progressing steadily
Kain Technology (688687): Rapid profit growth is in line with expectations, and the value of core products continues to be realized
Kain Technology (688687): Hepatitis C products are strong, and the hepatitis B field is ready to go
Kain Technology (688687): Functional cure for hepatitis B is imminent when the dose of the new hepatitis C drug is right
Kain Technology (688687) 2023 Third Quarter Report Review: The company's performance in the third quarter increased rapidly, and the cost control effect was remarkable
Kain Technology (688687): The performance of the third quarter report exceeded expectations, optimistic about Kailivir and the functional healing potential of hepatitis B
Kain Technology (688687): Continued expansion of new products and improved profitability
Kain Technology (688687) 2023 Q3 Report Review: Third Quarter Results Exceeded Expectations, Focus on Collection and R&D Progress
Analysis
Price Target
No Data
